Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 5
2010 3
2011 2
2012 3
2013 1
2015 4
2016 10
2017 12
2018 20
2019 23
2020 27
2021 30
2022 24
2023 18
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
Secondary diabetes mellitus in acromegaly.
Moustaki M, Paschou SA, Xekouki P, Kotsa K, Peppa M, Psaltopoulou T, Kalantaridou S, Vryonidou A. Moustaki M, et al. Among authors: kotsa k. Endocrine. 2023 Jul;81(1):1-15. doi: 10.1007/s12020-023-03339-1. Epub 2023 Mar 8. Endocrine. 2023. PMID: 36882643 Free PMC article. Review.
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Hernandez AF, et al. Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2. Lancet. 2018. PMID: 30291013 Clinical Trial.
GLP-1RAs for the treatment of obesity in women after menopause.
Paschou SA, Kotsa K, Peppa M, Hatziagelaki E, Psaltopoulou T. Paschou SA, et al. Among authors: kotsa k. Maturitas. 2022 Feb;156:65-66. doi: 10.1016/j.maturitas.2021.12.003. Epub 2021 Dec 11. Maturitas. 2022. PMID: 34922787 No abstract available.
GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use.
Arvanitakis K, Koufakis T, Popovic D, Maltese G, Mustafa O, Doumas M, Giouleme O, Kotsa K, Germanidis G. Arvanitakis K, et al. Among authors: kotsa k. Curr Obes Rep. 2023 Jun;12(2):61-74. doi: 10.1007/s13679-023-00506-3. Epub 2023 Apr 21. Curr Obes Rep. 2023. PMID: 37081371 Review.
Emerging incretin hormones actions: focus on bone metabolism.
Grammatiki M, Antonopoulou V, Kotsa K. Grammatiki M, et al. Among authors: kotsa k. Minerva Endocrinol. 2019 Sep;44(3):264-272. doi: 10.23736/S0391-1977.19.03008-6. Epub 2019 Apr 15. Minerva Endocrinol. 2019. PMID: 30991794 Review.
150 results